Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Operating Leases (2019 - 2025)

Cue Biopharma's Operating Leases history spans 7 years, with the latest figure at $2.7 million for Q3 2025.

  • For Q3 2025, Operating Leases rose 102.41% year-over-year to $2.7 million; the TTM value through Sep 2025 reached $2.7 million, up 102.41%, while the annual FY2024 figure was $1.0 million, 68.28% down from the prior year.
  • Operating Leases for Q3 2025 was $2.7 million at Cue Biopharma, down from $3.1 million in the prior quarter.
  • Across five years, Operating Leases topped out at $6.8 million in Q2 2022 and bottomed at $176000.0 in Q1 2025.
  • The 5-year median for Operating Leases is $3.1 million (2025), against an average of $3.1 million.
  • The largest annual shift saw Operating Leases tumbled 94.91% in 2022 before it skyrocketed 1113.35% in 2023.
  • A 5-year view of Operating Leases shows it stood at $5.1 million in 2021, then crashed by 94.91% to $260600.0 in 2022, then surged by 1113.35% to $3.2 million in 2023, then crashed by 68.28% to $1.0 million in 2024, then surged by 167.6% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Operating Leases are $2.7 million (Q3 2025), $3.1 million (Q2 2025), and $176000.0 (Q1 2025).